IOVS Journal of Bacteriology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2005;46:8-11.)
© 2005 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.04-0751
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Escalona-Benz, E.
Right arrow Articles by Windle, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Escalona-Benz, E.
Right arrow Articles by Windle, J. J.

Combretastatin A-4 Prodrug in the Treatment of a Murine Model of Retinoblastoma

Erika Escalona-Benz,1 Maria-Elena Jockovich,1 Timothy G. Murray,1 Brandy Hayden,1 Eleut Hernandez,1 William Feuer,1 and Jolene J. Windle2

1From the Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miami, Florida; and the 2Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.

PURPOSE. To evaluate the effect of subconjunctival injections of combretastatin A-4 phosphate (CA-4P) prodrug treatment on tumor vasculature and growth in an animal model of hereditary retinoblastoma.

METHODS. Twenty-four, 12-week-old simian virus-40 T-antigen–positive mice received six subconjunctival CA-4P injections at doses of 0.5, 1.0, 1.5, and 2.0 mg delivered at 72-hour intervals to the right eye only. Six control animals received placebo treatment. All animals underwent serial ophthalmic evaluations and were euthanatized at 16 weeks of age, and eyes were obtained for histopathologic examination. Eyes were graded for presence or absence of tumor, delay of tumor growth, and intratumoral vascularity.

RESULTS. The use of subconjunctivally injected CA-4P prodrug induced an extensive, dose-dependent decrease in microvessel density and led to significant tumor reduction in treated eyes compared with the placebo control (P < 0.001). No evidence of corneal, lenticular, choroidal, or retinal toxicity was observed by histopathologic evaluation.

CONCLUSIONS. Subconjunctival delivery of CA-4P is associated with extensive dose-dependent reduction in blood vessel count in this murine model of retinoblastoma. A combination treatment of retinoblastoma incorporating CA-4P may allow enhanced tumor reduction enabling a decrease in standard treatment doses of both chemotherapy and external beam radiotherapy.




This article has been cited by other articles:


Home page
 IOVSHome page
H. Boutrid, M.-E. Jockovich, T. G. Murray, Y. Pina, W. J. Feuer, T. J. Lampidis, and C. M. Cebulla
Targeting Hypoxia, a Novel Treatment for Advanced Retinoblastoma
Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 2799 - 2805.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M.-E. Jockovich, F. Suarez, A. Alegret, Y. Pina, B. Hayden, C. Cebulla, W. Feuer, and T. G. Murray
Mechanism of Retinoblastoma Tumor Cell Death after Focal Chemotherapy, Radiation, and Vascular Targeting Therapy in a Mouse Model
Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5371 - 5376.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
F. Suarez, M.-E. Jockovich, E. Hernandez, W. Feuer, J.-M. Parel, and T. G. Murray
Paclitaxel in the Treatment of Retinal Tumors of LH beta-Tag Murine Transgenic Model of Retinoblastoma
Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3437 - 3440.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. M. Carcaboso, G. F. Bramuglia, G. L. Chantada, A. C. Fandino, D. A. Chiappetta, M. T. G. de Davila, M. C. Rubio, and D. H. Abramson
Topotecan Vitreous Levels after Periocular or Intravenous Delivery in Rabbits: An Alternative for Retinoblastoma Chemotherapy
Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3761 - 3767.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M.-E. Jockovich, M. L. Bajenaru, Y. Pina, F. Suarez, W. Feuer, M. E. Fini, and T. G. Murray
Retinoblastoma Tumor Vessel Maturation Impacts Efficacy of Vessel Targeting in the LHBETATAG Mouse Model
Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2476 - 2482.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M.-E. Jockovich, T. G. Murray, E. Escalona-Benz, E. Hernandez, and W. Feuer
Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LHBETATAG Mice.
Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1264 - 1268.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Economopoulou, K. Bdeir, D. B. Cines, F. Fogt, Y. Bdeir, J. Lubkowski, W. Lu, K. T. Preissner, H.-P. Hammes, and T. Chavakis
Inhibition of pathologic retinal neovascularization by {alpha}-defensins
Blood, December 1, 2005; 106(12): 3831 - 3838.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Association for Research in Vision and Ophthalmology